HMOs are structurally complex, non-digestible oligosaccharides (e.g. 2'-Fucosyllactose, Lacto-N-neotetraose, 3-Fucosyllactose) produced by microbial fermentation or enzymatic synthesis.
They are the third-largest solid component of human breast milk and provide prebiotic, immune-modulating, anti-pathogenic and brain-development benefits. Increasingly added to premium infant formula.